Herpes simplex virus glycoprotein treatment of recurrent genital herpes reduces cervicovaginal virus shedding in guinea pigs

Antiviral Res. 1988 Nov;10(1-3):83-8. doi: 10.1016/0166-3542(88)90016-2.

Abstract

Treatment of previously infected guinea pigs with herpes simplex virus (HSV) glycoproteins reduces the frequency and severity of subsequent genital recurrences. An effective vaccine should also reduce episodes of viral shedding. In this study, HSV glycoproteins B and D treatment of animals experiencing recurrent genital herpes reduced the frequency of both clinical recurrences and cervicovaginal viral shedding. When virus was shed, however, the peak viral titer and duration of shedding was unaltered.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Cervix Uteri / microbiology
  • Female
  • Guinea Pigs
  • Herpes Genitalis / therapy*
  • Simplexvirus
  • Vagina / microbiology
  • Viral Envelope Proteins / therapeutic use*

Substances

  • Viral Envelope Proteins
  • glycoprotein B, herpes simplex virus type 2
  • glycoprotein D-herpes simplex virus type 2